<\/p>\n
NEW FILINGS<\/strong><\/p>\n Company: ECMOHO Limited Company: BRP Group, Inc. Company: BellRing Brands, Inc. Company: innate Pharma S.A. TERMS ADDED<\/strong><\/p>\n Company: MetroCity Bankshares Inc. Company: BioNTech SE Company: Frequency Therapeutics, Inc. Company: ADC Therapeutics SA Company: Aprea Therapeutics Inc. Company: Viela Bio, Inc.
\nSymbol: MOHO
\nDescription: They are one of China\u2019s leading integrated solution providers in the rapidly growing non-medical health and wellness market.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): UBS, CICC
\nFiled: 9-26-19
\nListed Cash Raise: $150m<\/p>\n
\nSymbol: BRP
\nDescription: They are a rapidly growing independent insurance distribution firm delivering solutions that give our clients the peace of mind to pursue their purpose, passion and dreams.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): J.P. Morgan, BofA Merrill Lynch, Jefferies, Wells Fargo Securities
\nCo-Manager: Raymond James, Keefe Bruyette & Woods
\nFiled: 9-23-19
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: BRBR
\nDescription: They are a rapidly growing leader in the global convenient nutrition category, aiming to enhance the lives of our consumers by providing them with highly nutritious, great-tasting products they can enjoy throughout the day.
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Morgan Stanley, Citigroup, J.P. Morgan, Goldman Sachs
\nCo-Manager: BofA Merrill Lynch, Barclays, BMO Capital Markets, Credit Suisse, Evercore ISI, Stifel, SunTrust Robinson Humphrey, Wells Fargo Securities, HSBC, Nomura, PNC Capital Markets, Rabo Securities, UBS Investment Bank
\nFiled: 9-20-19
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: IPHA
\nDescription: They are a biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. Their ordinary shares are listed on Euronext Paris under the symbol “IPH.”
\nShares: TBD
\nPrice Range: TBD
\nTrade Date: TBD
\nUnderwriter(s): Citigroup, SVB L:eerink, Evercore ISI
\nFiled: 9-20-19
\nListed Cash Raise: $100m<\/p>\n
\nSymbol: MCBS
\nDescription: They are MetroCity Bankshares, Inc., a bank holding company headquartered in the Atlanta metropolitan area. Their common stock is presently quoted on the OTC Market Group\u2019s OTCQX Market under the symbol \u201cMCBS.\u201d
\nShares: 1.939 million
\nPrice Range: $14.50-$16.50
\nMarket Cap: $370m-$420m
\nTrade Date: Thursday, 10\/3
\nUnderwriter(s): Keefe Bruyette & Woods, Raymond James
\nCo-manager(s): Hovde Group
\nTerms Added: 9-24-19<\/p>\n
\nSymbol: BNTX
\nDescription: BioNTech was founded in 2008 on the understanding that every cancer patient\u2019s tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient.
\nShares: 13.2 million ADSs
\nPrice Range: $18.00-$20.00
\nMarket Cap: $4.1b-$4.6b
\nTrade Date: Thursday, 10\/10
\nUnderwriter(s): JP Morgan, BofA Merrill Lynch, UBS Investment Bank, SVB Leerink
\nCo-Manager: Canaccord Genuity, Bryan Garnier & Co., Berenberg, Wolfe Capital Markets, Kempen, Mirae Asset Securities
\nTerms Added: 9-24-19<\/p>\n
\nSymbol: FREQ
\nDescription: They are a clinical-stage biotechnology company focused on harnessing the body\u2019s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
\nShares: 6.7 million
\nPrice Range: $14.00-$16.00
\nMarket Cap: $436m-$500m
\nTrade Date: Thursday, 10\/3
\nUnderwriter(s): J.P. Morgan, Goldman Sachs, Cowen
\nTerms Added: 9-23-19<\/p>\n
\nSymbol: ADCT
\nDescription: They are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors.
\nShares: 8.164 million
\nPrice Range: $23.00-$26.00
\nMarket Cap: $1.7b-$1.9b
\nTrade Date: Thursday, 10\/3
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch, Cowen
\nTerms Added: 9-23-19<\/p>\n
\nSymbol: APRE
\nDescription: They are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer.
\nShares: 5 million
\nPrice Range: $14.00-$16.00
\nMarket Cap: $270m-$310m
\nTrade Date: Thursday, 10\/3
\nUnderwriter(s): JP Morgan, Morgan Stanley, RBC Capital
\nTerms Added: 9-23-19<\/p>\n
\nSymbol: VIE
\nDescription: They are a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, which we collectively refer to as autoimmune diseases.
\nShares: 7.5 million
\nPrice Range: $19.00-$21.00
\nMarket Cap: $940m-$1.03b
\nTrade Date: Thursday, 10\/3
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, Cowen
\nCo-manager(s): Guggenheim
\nTerms Added: 9-23-19<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,1536],"tags":[],"class_list":["post-10149","post","type-post","status-publish","format-standard","hentry","category-ipo","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/10149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=10149"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/10149\/revisions"}],"predecessor-version":[{"id":10150,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/10149\/revisions\/10150"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=10149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=10149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=10149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}